• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Cybin Inc.

    9/9/24 2:06:12 PM ET
    $CYBN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYBN alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
    X None
    Entity Type
    0001833141
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    CYBIN INC.
    Jurisdiction of Incorporation/Organization
    ONTARIO, CANADA
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    CYBIN INC.
    Street Address 1 Street Address 2
    100 King St. West, Suite 5600
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    Toronto ONTARIO, CANADA M5X 1C9 (866) 292-4601

    3. Related Persons

    Last Name First Name Middle Name
    Drysdale Douglas
    Street Address 1 Street Address 2
    100 King St. West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Tziras George
    Street Address 1 Street Address 2
    100 King Street West Suite 560
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA V5X 1C9
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    So Eric
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Fahel Gabriel
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Glavine Paul
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cavers Greg
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bartlone Aaron
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Firestone Theresa
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Lawson Mark
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Froese Grant
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Hoskins Eric
    Street Address 1 Street Address 2
    100 King Street West Suite 5600
    City State/Province/Country ZIP/PostalCode
    Toronto ONTARIO, CANADA M5X 1C9
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
    X
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2024-08-15    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
    X Yes    No

    9. Type(s) of Securities Offered (select all that apply)

       Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security X Other (describe)
    Stock options exercisable at CAD$0.345 per share vesting in four quarterly tranches beginning September 30, 2024.

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number X None
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    Street Address 1 Street Address 2
    City State/Province/Country ZIP/Postal Code
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $3,249,666 USD
    or    Indefinite
    Total Amount Sold $0 USD
    Total Remaining to be Sold $3,249,666 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Total offering amount represents maximum potential proceeds from exercise of options. CAD$1.3715=USD$1.00

    14. Investors

    X
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    13
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    24

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    CYBIN INC. Greg Cavers Greg Cavers CFO 2024-09-09

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $CYBN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CYBN

    DatePrice TargetRatingAnalyst
    3/13/2025$35.00Buy
    Guggenheim
    11/22/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    11/19/2021Buy → Hold
    Maxim Group
    10/5/2021$7.00Outperform
    Oppenheimer
    8/26/2021$9.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $CYBN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

      - Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 - Cybin Inc. (NYSE:CYBN) (Cboe Canada: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the "Securities Purchase Agreement") with High Trail Special Situations LLC ("High Trail"), pursuant to which the Company agreed to sell and issue to Hi

      7/1/25 11:19:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Reports Fiscal Year 2025 Financial Results and Recent Business Highlights

      - Dosing is underway in the Phase 3 CYB003 PARADIGM program which comprises two 12-week randomized, double-blind, placebo-controlled studies (APPROACH™ and EMBRACE™) and a long-term extension study (EXTEND), with anticipated combined enrollment of approximately 550 patients1 - - Strengthened commercial preparations and manufacturing capabilities through partnerships with Osmind and Thermo Fisher Scientific, respectively - - APPROACH expects to enroll 220 participants at approximately 45 clinical sites across the United States1 - - Initiation of second CYB003 pivotal study EMBRACE and completion of CYB004 Phase 2 study in general anxiety disorder expected around mid-20251 - - Cash to

      6/30/25 10:03:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

      - Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 - Cybin Inc. (NYSE:CYBN) (Cboe Canada: CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the "Securities Purchase Agreement") with High Trail Special Situations LLC ("High Trail"), pursuant to which the Company agreed to sell and issue to Hi

      6/30/25 9:27:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Financials

    Live finance-specific insights

    See more
    • Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

      - 100% of participants were responsive to treatment and 71% of participants were in remission at 12 months after just two 16 mg doses of CYB003 - - Robust, long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score compared to baseline at 12 months after two 16 mg doses of CYB003 - - Findings validate dosing regimen and confirm that CYB003's effects are highly durable and offer sustained relief for MDD patients - - CYB003 continues to be well-tolerated and demonstrates an excellent safety profile - - Cybin's Phase 3 PARADIGM TM multinational pivotal program evaluating the efficacy and safety of CYB003 has been initiated - - Company to

      11/18/24 7:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

      - Company to host conference call and webcast at 8:00 a.m. ET on Monday, November 18, 2024 - - Presentation will also include discussion of its recently initiated Phase 3 PARADIGM program for CYB003 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and webcast on Monday, November 18, 2024 at 8:00 a.m. ET. The event will be hosted by Cybin's Chief Executive Officer, Doug Drysdale, and Cybin's Chief Medical Officer, Amir Inamdar, and will incl

      11/14/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder

      - Breakthrough Therapy Designation ("BTD") provides an expedited review pathway, as well as increased access to U.S. Food and Drug Administration ("FDA") guidance on trial design, with the potential to significantly reduce drug development timelines - - First known BTD granted by the FDA for an adjunctive psychedelic based therapy for the treatment of Major Depressive Disorder ("MDD") - - Robust, sustained and statistically significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses (16mg) - - Impressive mean 22-point reduction in Montgomery-Asberg Depression Rating Scale ("MADRS") score from baseline at four months -

      3/13/24 6:00:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Cybin Inc.

      SC 13G - CYBIN INC. (0001833141) (Subject)

      12/3/24 5:23:26 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 7:51:22 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cybin Inc.

      SC 13G/A - CYBIN INC. (0001833141) (Subject)

      11/14/24 6:55:13 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    SEC Filings

    See more
    • SEC Form 6-K filed by Cybin Inc.

      6-K - CYBIN INC. (0001833141) (Filer)

      7/14/25 5:25:33 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SUPPL filed by Cybin Inc.

      SUPPL - CYBIN INC. (0001833141) (Filer)

      7/14/25 5:19:49 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form D filed by Cybin Inc.

      D - CYBIN INC. (0001833141) (Filer)

      7/10/25 3:36:10 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Cybin with a new price target

      Guggenheim initiated coverage of Cybin with a rating of Buy and set a new price target of $35.00

      3/13/25 7:34:44 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Cybin with a new price target

      HC Wainwright & Co. reiterated coverage of Cybin with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      11/22/21 6:24:49 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin downgraded by Maxim Group

      Maxim Group downgraded Cybin from Buy to Hold

      11/19/21 8:09:52 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CYBN
    Leadership Updates

    Live Leadership Updates

    See more
    • Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

      - Strategic Partnership Agreements promote collaboration and aligned incentives across sites, enhancing operational efficiency and improving site performance and patient recruitment - - Phase 2 data confirmed that two 16 mg doses of CYB003 administered three weeks apart provides remission from depression symptoms for 12 months in 71% of MDD patients - - Patient dosing continues in APPROACH, Cybin's first pivotal Phase 3 study of CYB003 for the adjunctive treatment for Major Depressive Disorder ("MDD") - - Second Phase 3 study, EMBRACE, is expected to begin mid-2025 - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry platform

      4/23/25 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

      - Company is on track to initiate its global Phase 3 pivotal program for CYB003 in Major Depressive Disorder ("MDD") imminently - - Cybin welcomes Dr. Mirza Rahman as Senior Vice President, Patient Safety & Pharmacovigilance and Dr. Marcelo Gutierrez as Vice President, Clinical Pharmacology - - Other recent additions to the team include project directors. project managers, and clinical monitoring managers, as well as previously announced senior leadership team hires, and program lead for CYB003 - - Strengthened team in place to support CYB003 pivotal trials, which will consist of three studies spanning up to 12 countries - Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company")

      10/1/24 7:30:00 AM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

      Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) (Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on August 27, 2024 (the "Meeting"). There were 87 shareholders represented in person or by proxy at the Meeting holding 453,195,063 common shares, representing 59.66% of Cybin's total issued and outstanding common shares as at the record date for the Meeting. The voting results for each matter presented at the Meeting are

      8/27/24 7:01:00 PM ET
      $CYBN
      Biotechnology: Pharmaceutical Preparations
      Health Care